CME in Minutes: Education in Dermatology

Please visit answersincme.com/860/IME-020568-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jeffrey M. Cohen, MD, MPH; Kristine Kucera, PA-C, MPAS, DHSc; and Lauren E. Miller, MPAS, PA-C. In this activity, experts in dermatology discuss the evolving role of next-generation TYK2 inhibitors in the treatment of patients with moderate to severe psoriasis. Upon completion of this activity, participants should be better able to: Explain the clinical rationale for TYK2 inhibitors in the management of patients with moderate to severe psoriasis; Differentiate the mechanism of action of TYK2 inhibition from other oral treatment options used for patients with moderate to severe psoriasis; and Apply available clinical evidence to identify patients with moderate to severe plaque psoriasis who may be appropriate candidates for TYK2 inhibitor therapy within current treatment paradigms. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/MRQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alexandra K. Golant, MD; Peter Lio, MD, FAAD; and Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP. In this activity, experts in dermatology discuss the OX40L pathway and its potential role in the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting the OX40/OX40 ligand (OX40L) pathway in the treatment of moderate-to-severe atopic dermatitis (AD); Assess the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD, including quality of life (QoL) impact; Integrate QoL assessments into shared decision-making with patients who have moderate or severe AD; and Outline strategies for enhancing the multidisciplinary management of moderate-to-severe AD.

Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better able to: Identify prognostic features of advanced systemic mastocytosis (AdvSM) that guide diagnosis and care planning; Describe current and emerging treatment options for patients with AdvSM; and Evaluate patient- and disease-related strategies that inform treatment selection in AdvSM.

Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients’ quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–targeting TKIs into the management of ISM.

Please visit answersincme.com/860/IME-018263-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by April W. Armstrong, MD, MPH and Lawrence J. Green, MD. In this activity, experts in psoriasis review the latest evidence on approved and emerging TYK2 inhibitors for patients with moderate to severe plaque psoriasis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the treatment of patients with moderate to severe plaque psoriasis; Differentiate TYK2 signaling from JAK pathways and their relevance to clinical practice; and Review clinical trial data on approved and emerging TYK2 inhibitors for patients with moderate to severe plaque psoriasis.